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INTRODUCTION 
Taste is an important factor in the development of dosage 
form. The problem of bitter and obnoxious taste of drug 
in pediatric and geriatric formulations is a challenge to 
the pharmacist in the present scenario. The major 
problem of these both drugs was very low solubility & 
bitter taste. Children  are  frequently  failed  to  take  
medications  properly  because  of  unpleasant  taste  of  
medicament.  Non-compliance can lead to 
worsening of diseased condition. Numbers 
of taste masking technologies have been used to address t
he problem of patient compliance.1 
In  Ion  exchange  resin  (IER)  method  weak  cat ion  
exchange  or  weak  anion  exchange  resins  are  used  
for  taste  masking,  depending  on  the  nature  of  
drug. Ion exchange resins are solid and suitably insoluble 
high molecular weight polyelectrolyte that can exchange 
their mobile ions of equal charge with the surrounding 
medium. 
Malaria is an infectious disease of tropical areas caused 
by the parasitic infestation of red blood cells by a 
protozoan of the genus Plasmodium, which is transmitted 
by the bite of an infected female Anopheles mosquito . 
Four Plasmodia species which commonly infect humans 
are P. falciparum, P. malariae, P. vivax and P.ovale. All 
four species are found in the tropics and sub-tropics 
around the world. Chlorquine phosphate is potent anti 
malarial agent prescribed for treating of malaria. It’s 
used for malaria prophylaxis, and appears to be safe . 
Active against the erthyrocytic forms of Plasmodium 
vivax, Plasmodium malariae, and susceptible strains of 
Plasmodium falciparum. It is very bitter drug. Currently, 
there is no pharmaceutical alternative to circumvent the 
compliance problem for Chloroquine phosphate and thus 
taste masking is necessary to achieve an improved 
patient compliance to this drug especially in children2. 
MATERIALS 
All the materials were procured from by shreya life 
sciences, Aurangabad. All chemicals were of analytical 
grade. 
Preparation of syrup base: 
 For this, required quantity of water was taken 
in a 500 ml stainless steel container, and it was heated to 
95ºC. To this, required quantity of methyl paraben and 
propyl paraben was added with stirring to get clear 
solution. To this, required quantity of sucrose was added 
with continuous stirring to dissolve completely. Finally, 
the prepared syrup base was cooled upto 45ºC. 
Addition of drug 
For this, the above prepared syrup base was transferred 
into a clean 500 ml stainless steel vessel. To this, 
weighed quantity of drug was slowly added with 
constant stirring, followed by sucralose. The solution 
was homogenized for 30 min and finally, it was 
transferred into amber coloured PET glass bottles of    25 
ml. 
Table 1: Composition of dispersion of Chloroquine 
phosphate with sucralose 
Sr.No. Batch code Ratios of Chloroquine 
phosphate :sucralose 
1 CPSU1a 1:1 
2 CPSU1b 1:3 
3 CPSU1c 1:5 
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The same procedure was carried out for the preparation 
of dispersion of Chloroquine phosphate with syrup base 
containing sodium saccharin as sweetener. 
Table 2: Composition of dispersion of Chloroquine 
phosphate with saccharin sodium 
Sr.No. Batch 
code 
Ratios of Chloroquine 
phosphate :sodium saccharin 
1 CPSS2a 1:1 
2 CPSS2b 1:3 
3 CPSS2c 1:5 
 
Preparation of drug: resin complexes (resinate)
5 
For this, batch process was used (Table No.3). The major 
steps are enlisted below.53 
 Dispersion of resin (2g) in 100ml deionised water 
and stirring for 20 min with the help of magnetic 
stirrer. 
 Addition of Chloroquine phosphate (500 mg) slowly 
with constant stirring. 
 Stirring over 4 hrs and pH adjustment with acid (1M 
HCl) to pH 5. 
 Separation of resinate by vacuum filtration through 
Whatman filter paper (No. 41) and washing with 
deionised water (3-4 portions of 25 ml each) to 
remove uncomplexed drug. 
 Drying of resinate overnight at room temperature 
(35±2o C)  
 Labelling and storage in tightly closed light 
resistance container. 
 
Evaluation of dispersions of Chloroquine phosphate 
with sweeteners
6,7 
The dispersions were evaluated for the following 
characteristics: 
1. Organoleptic properties viz. color, odor and taste 
2. Functional properties: 
a)   Contents of drug 
b)   Viscosity  
1. Organoleptic properties 
Organoleptic properties viz. colour, odour and taste of 
dispersions were recorded. Colour was noted by visual 
observation, odour was checked by individual subjective 
perception and taste was tested by three panels of tastes. 
Functional properties 
Contents of drug 
 For this, the dispersion of sweeteners equivalent to 
300 mg of Chloroquine phosphate was accurately 
weighed and transferred into 100 ml volumetric 
flask, containing 0.1 M HCl (15-20 ml). 
 The volume was made up to 100 ml using 0.1 M 
HCl and stirred using magnetic stirrer for 30 min. 
 The solution was filtered through whatmann filter 
paper no 41  and from the filtrate, 5ml was diluted to 
100 ml.  
 The drug content was noted spectrophotometrically 
at a previously determined λmax value. 
Viscosity  
The viscosity of dispersion was determined at ambient 
conditions. For this, 15ml of dispersion was taken in a 
small sample adapter and the adapter was set over the 
viscometer by a stand in such a way that spindle (No.2) 
was completely immersed in the suspension. Spindle was 
used at 50 rpm. 
2.  Dispersion of syrup base with viscosity enhancers 
1. Use of tragacanth gum  
Preparation of syrup base 
For this, required quantity of water was taken in a 500 ml 
stainless steel container, and heated up to 95ºC. To this, 
required quantities of methyl paraben and propyl paraben 
were added and solution was stirred till it became clear. 
To this, required quantity of sucrose was added with 
continuous stirring. Finally, the  syrup base was cooled 
to 45ºC. the prepared syrup base was transferred into a 
clean s.s vessel (500 ml) provided with overhead 
homogenizer. To this, the drug was slowly added with 
constant stirring, followed by addition of gum tragacanth 
solution (1% w/v) and stirring was continued for 30 min. 
The dispersion was transferred into amber coloured glass 
bottles of capacity 25 ml.3 
Table 3: Composition of dispersions of Chloroquine 
phosphate with gum tragacanth 
Sr.No Batch code 
 
Addition of gum tragacant 
solution (1%   w/w/) 
1 CPG1a 1 ml 
2 CPG1b 3 ml 
3 CPG1c 5ml 
 
Use of glycerine: 
For this, same procedure used for preparation of 
dispersion of drug containing gum tragacanth was 
followed except the gum was replaced with appropriate 
quantity of glycerin (Table No. 5).  
Table 4: Composition of dispersions of Chloroquine 
phosphate with glycerin 
S.No. Batch code Addition of glycerrine 
( 5%   w/v/) 
1 CPGL2a 1 ml 
2 CPGL2b 3 ml 
3 CPGL2c 5ml 
 
Evaluation of dispersion with viscosity enhancers
5 
The dispersion was evaluated for the following 
characteristics: 
a) Contents of drug 
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 For this, the dispersion with viscosity enhancer’s 
equivalent to 300 mg of Chloroquine phosphate was 
accurately weighed and transferred into 100 ml 
volumetric flask, containing 0.1 M HCl (15-20 ml). 
 The volume was made up to 100 ml using 0.1 M 
HCl and stirred using magnetic stirrer for 30 min. 
 The solution was filtered through Whatman filter 
paper no 41 and from the filtrate, 5ml was diluted to 
100 ml.  
 The drug content was noted spectrophotometrically 
at a previously determined λmax value. 
b)Viscosity  
The viscosity of dispersion was determined at ambient 
conditions. For this, 15ml of suspension was taken in an 
small sample adapter, and the adapter was set over the 
viscometer by a stand in such a way that spindle (No. 2) 
was completely immersed in the dispersion.  
II. Complexation with ion exchange resins   
The drug resin complexes were prepared using two 
different cation exchange resins using following 
procedure. 
1. Characterization of resins 
2. Activation/purification  of resins  
3. Preparation of  drug resin complexes (resinates)  
d. Activation/purification of resin 
Resins were purified by following procedure  
 5g quantities of individual resin were accurately 
weighed and taken into beaker (250ml) containing 
100 ml of deionised water. The slurry was stirred 
using magnetic stirrer for 15 min. The dispersion 
was then filtered through Whatman filter paper (No. 
41) and filtrate was discarded. 
 The resin mass was washed with methanol (99.8% 
v/v, 50ml in divide portions) and then with 
deionised water (50ml) to remove organic and 
coloured impurities if any. 
 The wet resin was treated with 1M HCl (100 ml) for 
1 hr with continuous stirring using magnetic stirrer. 
 The dispersion was filtered through Whatman filter 
paper(No.41) and rinsed with about 20ml deionised 
water for several times. The pH of washing was 
noted and washing was continued till the pH of the 
filtrate became neutral or near to neutral. 
The liquid form resin mass was drained using suction. 
The resin mass was dried overnight at 50ºC± 2oC in hot 
air oven. 
 
Table 5: Composition of resinates of Chloroquine phosphate and resins 
 
 
 
 
 
 
 
 
 
 
Drying of resinate overnight at room temperature (35±2o 
C)  
 Labelling and storage in tightly closed light 
resistance container. 
C. Evaluation of resinates
8 
The taste masked drug samples prepared using resins 
were evaluated for the following characteristics: 
1 Organoleptic properties viz. color, odor and taste 
2. Functional properties: 
i   Estimation of drug loading in resinate 
iii Interpretation of infrared spectra of  individual resin 
and their resinates   
iv. Evaluation of taste of resinates by panel of tastees 
1. Organoleptic properties 
Organoleptic properties viz. colour, odour and taste of 
resinates were recorded by following the same 
procedures as described for dispersion with sweeteners. 
2. Functional properties 
i. Estimation of drug loading in resinates 
 For this, the resinate equivalent to 80 mg of 
Chloroquine was accurately weighed and transferred 
into 100 ml volumetric flask, containing 0.1 M HCl 
(15-20 ml). 
 The volume was made up to 100 ml using 0.1 M 
HCl and stirred using magnetic      
 stirrer for 30 min. 
 The solution was filtered and further dilutions of 
filtrate were made.  
Type of resin Resinate code Ratios of Chloroquine 
phosphate: resin 
 
Doshion P-544 S 
CPR1a 1:1 
CPR1b 1:2 
CPR1c 1:3 
CPR1d 1:4 
 
    Kyron T 114 
CPR2a 1:1 
CPR2b 1:2 
CPR2c 1:3 
CPR2d 1:4 
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 The drug content was estimated 
spectrophotometrically Absorbance was noted at 
previously determined λmax value. 
 
ii. Interpretation of infrared spectra of individual 
resins, drug and drug resin complexes   
 IR spectra of individual resin and resinates of 
drug were recorded following the same procedure as 
described for dispersion with sweeteners. 
Mixing of DR complex with syrup
9 
 For this, the drug resin complex (1:4) (mother liquor) 
was added in to the syrup base with constant stirring. To 
this, required quantities of coloring and flavoring agents 
were added and stirring was continued for 10 min. The 
final volume of suspension was made up to required 
quantity using purified water. 
Formulation of suspension containing Drug: Doshion 
P-544s (1:4) resinate and viscosity modifier.  
For this, 100ml purified water was taken in 500ml vessel 
(S.S.) and was   heated upto 95ºC.To this, required 
quantities of preservatives were added followed by 
sucrose. Syrup base was cooled at 45ºC. 
The drug resin complex (1:4)(mother liquor) was added 
into the syrup base with continuous stirring. The aqueous 
dispersion of required quantity of xanthum gum   was 
prepared and added to the syrup containing drug resin 
complex. To this, required volume of aqueous solution of 
methanol was added followed by the colour sunset 
yellow FCF w/s and mixed fruit flavor as a flavoring 
agent with continuous stirring. 
Final volume of the suspension was made up to the 
required quantity, and the bulk was stirred further for 30 
min, and finally the pH of the suspension was adjusted 
between 5.8 to 6.4 using 10%w/v citric acid solution. 
The typical formulation of taste masked Chloroquine 
phosphate suspension included the selected taste 
modified drug form and following excipients. 
 
Table 6: Composition of suspension containing Chloroquine phosphate: Doshion P 544S (1:4) resinate 
Sr.No Ingredient Category CPR1 CPR2 CPR3 
1 Chloroquine phosphate Antimalarial 4.8gm 4.8gm 4.8gm 
2 Doshion P-544s Complexing agent   19.2gm 19.2gm 19.2gm 
3 Pharma grade sugar Sweetner 105gm 105gm 105gm 
4 Methyl paraben Preservative 2.4gm 2.4gm 2.4gm 
5 Propyl paraben Preservative 0.6gm 0.6gm 0.6gm 
6 Xanthum gum Suspending agent 0.131gm 0.262gm 0.525gm 
7 Sucralose Sweetner 750mg 750mg 750mg 
8 Menthol Taste enhancer/Cooling agent 1.98mg 1.98mg 1.98mg 
9 Colour sunset yellow FCFw/s Colourant 0.024ml 0.024ml 0.024ml 
10 Mixed fruit flavour Flavour 1.5ml 1.5ml 1.5ml 
11 Purified water Suspension medium qs to 300ml qs to 300ml qs to 300ml 
 
E. Evaluation of Chloroquine phosphate suspension 
The suspension was evaluated for following compendia 
and non compendia parameters 
Sedimentation volume
 
The formulated suspension was evaluated for physical 
stability by determining the sedimentation volume. Fifty 
ml each of suspension was taken in 50 ml stoppered 
graduated measuring cylinder. The suspension was 
dispersed thoroughly by moving upside down for three 
times. Later, the suspension was allowed to settle over 
three minutes and the volume of sediment was noted. 
(H0). The cylinder was kept undisturbed for 7 days. The 
volume of sediment read at and on 7th day was 
considered as final volume of sediment (H)u. 
Sedimentation Volume (F) = Hu/ Ho.10 
Redispersiblity: 
For this, (50 ml) suspension was kept in two (A and B) 
stoppered cylinder which was stored at room temperature 
(35±2ºC) for 7 days. At regular interval, one stoppered 
cylinder (A) was removed and moved upside down until 
there was no sediment at the bottom of the cylinder. 
Assay
 
For this, 10 ml of suspension was taken in 100 ml 
volumetric flask and the volume was made up to 100 ml 
using 0.1 M HCl. Then 2 ml of solution from the flask 
was withdraw and added into 200 ml volumetric flask. 
Again the volume was made up to 200 ml with 0.1 M 
HCl, was filtered through whattman filter paper No.41 
and absorbance was measured at wavelength at 343 nm 
in U.V sphectrophotometer and compare it with 
standard.11 
In vitro drug release: 
Dissolution test parameters 
Dissolution test apparatus :  USP XXII type II (paddle) 
Dissolution medium :  500 ml 0.1 M HCl 
Temperature of medium     :  37 ±0.50C 
Speed of rotating paddle    :  50 rpm 
Sampling volume               :  10 ml 
Sampling time                    :  10, 20, 30, 40, 50 & 60 min 
Duration of test                  :  60 min 
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Wavelength for estimation of the drug from the 
suspension was tested using USP – type II dissolution 
apparatus .In each of the 6 flashes.10 ml of the 
suspension was added into the dissolution medium and 
the test was carried out at above mentioned conditions. 
The dissolution medium, 500ml 0.1M HCL, was placed 
into the dissolution flask maintaining the temperature of 
37°C± 0.5°C and rpm of 50. Suspension (10ml) was 
placed in each flask of dissolution apparatus The 
apparatus was allowed to run for 60 minutes. Samples 
measuring 10 ml were withdrawn after every 10, 20, 30, 
40, 50 and 60 min manually. During sampling samples 
were filtered through 0.45 μm filter. The fresh 
dissolution medium was replaced every time with the 
same quantity of the sample Collected samples were 
withdrawn, filtered and suitably diluted and analysed at 
343nm using U.V spectrophotometer.13, 14 
Zeta potential 
The zeta potential was measured in triplicates in 
multimodal mode. The technique opted was Malvern 
zetasizer inspection system (Malvern UK) respectively at 
250C. Prior to the measurement, Suspension was diluted 
with distilled water and the measurements were taken in 
triplicate.12 
Comparison of optimized batch with marketed 
formulation 
The optimized formulation of Chloroquine phosphate 
suspension was compared with that of marketed 
formulation for various testing parameters as per the 
procedure mentioned in section  
Stability studies  
The Chloroquine phosphate oral suspension of the 
optimized formulation (CPR3) was selected and was 
packed in 60ml amber colour PET bottle with ROPP cap. 
The packed bottles were stored at the controlled 
environmental conditions (Temperature 40 ± 20 C and 
RH 75 ± 5 %) for 90 days .Samples was collected at days 
0, 30, 60 and 90.15 
The analyses comprised chemical testing of quantifiable 
parameters, which could possibly change during storage, 
such as viscosity, pH, drug contents, sedimentation 
volume, redispersiblity, colour, taste, odour and assay, 
drug release were recorded. 
RESULT AND DISCUSSIONS 
Drug loading of Chloroquine phosphate in resinate 
Drug loading studies revealed that as the concentration 
of resin increases, percentage drug loading also 
increases. For Doshion P 544 S, drug loading was found 
to increase from 81.77% to 98.62% as drug: resin ratio 
increased from 1:1 to 1:4. For Kyron T114, drug loading 
increased from 79.63%-96.12% as drug :resin ratio 
increased from 1:1-1:4. Resinates prepared with Doshion 
P 544 S exhibits higher drug loading as compared to 
Kyron T 114. 
 
Table 7: Loading of drug in resinates 
 
5.1 Effect of pH:  
The pH of the resinates affected both solubility and the degree of ionization of drug and resin (Table No. 8.37). The 
resinate at selected ratio (1:4) indicated maximum loading of drug at pH 6.00. This may due to the fact that at this pH 
there was ionization of Doshion (pKa=2-8) allowing exchange with cations from the drug molecule. Hence, pH 6.0 was 
considere to be most suitable. 
Table 8: Effect of pH 
 
 
 
 
 
 
Type of Chloroquine phosphate  
resinate  
   Resinate code Ratios of Chloroquine 
phosphate:resin 
% w/w loading of 
drug 
 
Chloroquine phosphate : Doshion 
P 544S 
CPR1a 1:1 81.66 
CPR1b 1:2 89.17 
CPR1c 1:3 95.13 
CPR1d 1:4 98.62 
 
Chlorquine  phosphate : Kyron T 
114 
CPR2a 1:1 79.63 
   
CPR2b 1:2 86.32 
CPR2c 1:3 92.44 
CPR2d 1:4 96.12 
 
Sr. No. 
Chloroquine phophate :  Doshion P 544 S (1:4) 
Resinate code pH % loading of drug 
1 CPR1dP1 3 90.24 
2 CPR1dP2 4 90.94 
3 CPR1dP3 5 96.79 
4 CPR1dP4 6 97.12 
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5.2: Effect of stirring time: 
The percentage drug loading gradually increased with time for stirring upto 5 hrs (Table No. 8.38 ). However, 
thereafter, the increment was minimal, hence, stirring time of 5 hrs was considered most suitable. 
Table 9: Effect of stirring time 
   
 
 
 
 
 
 
5.3 Effect of temperature:  
Drug loading on Doshion P 544 S was observed in the experimental range of 20ºC-60ºC (Table No. 8.39). However, 
higher temperatures did not affect the drug loading considerably. Hence, room temperature (35-37 OC) was employed 
for preparation of resinates. 
Table 10: Effect of temperature 
 
 
 
 
 
 
Based on the above findings, the resinate with Doshion P 544 S was prepared at following selected conditions (Table 
No 11 ). 
Table 11: Experimental parameters for preparation of resinate with Doshion P544 S. 
 
 
 
 
 
 
In vitro drug release 
Drug release form batch CPR3 was constant and faster compared to other two batches due to uniform suspending of 
drug molecule. In 30 minutes it is 83.31% while in 60 minutes it is 99% release. 
Table 12: Release data of Chloroquine phosphate from suspension in 0.1M HCl 
 
(Mean ± SD, n-3) 
 
Sr. No. 
Chloroquine phosphate :  Doshion P 544 S (1:4) 
Resinate code Stirring time (hr) % Drug loading 
1 CPR1dH1 2 90.62 
2 CPR1dH2 3 91.17 
3 CPR1dH3 4 95.56 
4 CPR1dH4 5 98.16 
 
 
    Sr. No. 
Chloroquine phosphate :  Doshion P 544 S (1:4) 
Resinate code Temperature 
o
C (± 2 oC ) % Drug loading 
1 CPR1dT1 Room Temp (35) 97.61 
2 CPR1dT2 20 96.63 
3 CPR1dT3 40 97.13 
4 CPR1dT4 60 96.81 
Sr. No. Type of parameter Selected value 
1 Drug: resin ratio 1:4 
2 pH 6.00 
3 Stirring time 5 hr 
4 Temperature 35º±2ºC 
Time  % drug release 
(min  CPR1 CPR2 CPR3 
0 0 0 0 
10 49.7±058 52.6±0..2 53.23±0.67 
20 61.40±0.41 63.24±0.11 64.44±0.23 
30 79.63±0.67 81.20±0.16 83.31±0.36 
40 89.82±0.16 90.42±0.08 93.48±0.08 
50 95.67±0.38 96.11±0.41 98.56±0.12 
60 97.06±0.17 98.45±0.28 99.09±0.10 
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Figure 1:    Percent cumulative release of Chloroquine phosphate from suspension 
Zeta potential of selected batch CPR3: 
The zeta potential of prepared formulation suspension 
(Batch CPR3) was determined as per the procedure 
mentioned in experimental part 7.4.h; and the results are 
illustrated in figure 8.20 
If all the particles have a large negative or the positive 
zeta potential they will repel each other and there is 
dispersion stability. If the particles have low zeta 
potential values then there is no force to prevent the 
particles coming together and there is dispersion 
instability. Particles with zeta potentials more than -
30mV are normally considered stable. Zeta potential of 
the system was found to be -25.1.00 mV, which 
indicated the suspension having negative charge, which 
is closer to range.12 
 
 
Figure 2: Zeta potential of suspension of Chloroquine phosphate resinate- CPR3 
Characteristics of commercial product of Chloroquine phosphate 
Comparision of experimental suspension with marketed formulation represents superiority of experimental formulation 
mainly in taste and in redispersibility. 
Table 13: Characteristics of experimental suspension and  marketed formulation 
Characteristics Marketed preparation 
(M) 
Experimental suspension  
(CPR3) 
  Colour Sunset yellow Sunset yellow 
Odour Odourless Odourless 
Taste Palatable Sweet 
pH 6.4 6.2 
Viscosity(cps) 10016 12516 
Sedimentation volume 0.96 0.98 
Redispersibility *** **** 
Assay* 98.01±0.2 97.2±0.6 
(* Mean ± SD, n=3) 
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Table 14: Release characteristics of Chloroquine phosphate from experimental suspension and marketed 
Lariago suspension 
  
 
 
                             
 
 
 
 
 
 
Figure 3: Release profiles of Chloroquine phosphate from experimental suspension and commercial Lariago
® 
suspension 
Stability characteristics: 
The exposure to accelerated conditions (temperature 40 ± 20 C and RH 75 ± 5 %)  revealed that the experimental 
suspension  did not undergo considerable  changes in assay, sedimentation volume, viscosity, and redispersibility. 
Moreover, it retained sweet taste during the period of exposure (Table No.8.51). The release characteristics of drug 
complex from suspension were fairly constant during the period of 90 days. 
Table 15: Characteristics of experimental suspension samples during storage over 90 days  
Characteristics Time point 
0 days 15 days 30 days 90days 
Colour Sunset yellow Sunset yellow Sunset yellow Sunset yellow 
Odour Odourless Odourless Odourless Odourless 
Taste Sweet Sweet Sweet Sweet 
pH 6.20 6.20 6.30 6.20 
Viscosity(cps) 12516 12518 12518 12517 
Sedimentation volume 0.98 0.98 0.97 0.97 
Redispersibility **** **** **** **** 
Assay* 97.20 97.30 97.10 97.20 
  
Release profile of stable suspension indicates constant and proportionate release in definte time at all intervals and 
similar at 90 days. 
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Time ( min.) Cumulative drug release (%)  
M CPR3 
0 0 0 
10 51.06±0.88 53.23±0.67 
20 65.06±0.32 64.44±0.23 
30 82.01±0.69 83.31±0.36 
40 91.06±0.41 93.48±0.08 
50 97.63±0.89 98.56±0.12 
60 98.97±0.52 99.09±0.10 
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Table 16: Release characteristics of experimental suspension samples during storage over 90 days 
 
 
 
 
 
 
 
 
Figure 4:  Release profiles of Chloroquine phosphate from experimental suspension stored for 90 days 
 
CONCLUSIONS 
The efficient taste masking was obtained from drug–resin a 
complex that was formulated as oral suspension for better 
patient compliance. Use of weak cation exchange resin 
offers superior method for preparing taste-masked 
substrates of Chloroquine phosphate in this work shows that 
drug-resin complexes effectively masked bitter taste of 
Chloroquine phosphate while liquid formulation provides 
easier way to administer and getting the child to swallow. 
The Intense bitter taste of Chloroquine phosphate can be 
successfully masked by complexation using weak cation 
exchange resin Doshion P 544 S. The resinate of drug: 
Doshion P 544 S given higher drug loading and better taste 
masking. It can be concluded that, the complex of 
Chloroquine phosphate with Doshion P 544 S can be 
successfully prepared to mask the intense bitter taste of 
Chloroquine phosphate. The taste masked suspension of 
resinate prepared will be suitable formulation for patient’s 
to treat malaria. 
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Time (min)
0 days
15 days
30 Days
90days
Time (in min.) Cumulative drug release (%)  
0 days 15 days 30 Days 90days 
0 0  0 0 
10 53.23±0.67 54.23±0.87 55.23±0.66 57.23±0.64 
20 64.44±0.23 66.44±0.73 67.44±0.24 68.44±0.33 
30 83.31±0.36 84.81±0.96 86.31±0.76 87.31±0.36 
40 93.48±0.08 94.48±0.88 96.48±0.58 97.48±0.18 
50 98.56±0.12 98.06±0.12 98.56±0.42 98.56±0.92 
60 99.09±0.10 99.09±0.15 99.09±0.18 99.09±0.28 
